A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Conditions
Alzheimer Disease · Psychosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Gilbert Neurology Partners/CCT Research, Gilbert, Arizona, United States
Inland Psychiatric Medical Group., Chino, California, United States
Local Institution - 0001, Naples, Florida, United States
Local Institution - 1401, Naples, Florida, United States
Local Institution - 0029, Cleveland, Ohio, United States
Insight Clinical Trials LLC - Independence, Independence, Ohio, United States
Local Institution - 0020, Macquarie Park, New South Wales, Australia
Local Institution - 0052, Nedlands, Western Australia, Australia
Local Institution - 0054, Toronto, Ontario, Canada
Local Institution - 0027, Whitby, Ontario, Canada
Local Institution - 0025, Montreal, Quebec, Canada
Local Institution - 0040, Suita, Osaka, Japan
Local Institution - 0035, Nankoku-shi, Japan
Local Institution - 0034, Osaka, Japan
Local Institution - 0005, Exeter, Devon, United Kingdom
Local Institution - 0023, London, England, United Kingdom
Local Institution - 0015, Oxford, Oxfordshire, United Kingdom
Local Institution - 0009, Chertsey, Surrey, United Kingdom
Local Institution - 0017, Sheffield, Yorkshire and the Humber, United Kingdom
Local Institution - 0018, Crowborough, United Kingdom
Local Institution - 0024, London, United Kingdom
Local Institution - 0004, Motherwell, United Kingdom
Study leads
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb